Developed by Shray Alag, The Harker School
Sections: Correlations,
Clinical Trials, and HPO
Navigate: Clinical Trials and HPO
| Name (Synonyms) | Correlation | |
|---|---|---|
| D013577 | Syndrome NIH | 0.09 |
| D012127 | Respiratory Distress Syndrome, Newborn NIH | 0.08 |
| D055371 | Acute Lung Injury NIH | 0.08 |
| Name (Synonyms) | Correlation |
|---|
Navigate: Correlations HPO
There is one clinical trial.
This protocol provides access to investigational convalescent plasma for hospitalized patients with COVID-19. Following provision of informed consent, patients will be administered around 500 mL of convalescent plasma obtained from an individual who has recovered from a documented SARS-CoV-2 infection. The study aims to evaluate the efficacy and safety of anti-SARS-CoV-2 convalescent plasma as adjunctive therapy in preventing disease progression (prevention of ICU admission) among hospitalized patients with COVID-19. Safety outcomes include serious adverse events judged to be related to convalescent plasma. Other information which will be collected includes patient demographics and clinical data which includes quick SOFA scores, ventilator-free days, ICU-free days, dialysis-free days and 28-day mortality.
Description: Cumulative incidence of serious adverse events (transfusion-related acute lung injury, transfusion associated circulatory overload, transfusion related infection and anaphylaxis/severe allergic reactions) during the study period
Measure: Incidence of serious adverse events Time: 28 days from enrollmentDescription: Quick Sequential Organ Failure Assessment (qSOFA) scores of study participants within 28 days from enrollment. The qSOFA score is a rapid bedside clinical score used to identify patients with suspected infection that are at a greater risk for a poor outcome. Minimum score is 0 and maximum score is 3. A higher score is associated with higher risk for in-hospital mortality.
Measure: Quick SOFA (qSOFA) score Time: 28 days from enrollmentDescription: Total number of patients experiencing cardiopulmonary arrest
Measure: Cardiopulmonary arrest Time: 28 days from enrollmentDescription: Total number of deaths among patients admitted to the ICU
Measure: ICU mortality Time: 28 days from enrollmentDescription: Total number of days patients were admitted to the ICU
Measure: ICU length of stay Time: 28 days from enrollmentDescription: Total number of deaths among study participants
Measure: Hospital mortality Time: 28 days from enrollmentDescription: Total number of days patients were admitted to the hospital
Measure: Hospital length of stay Time: 28 days from enrollmentDescription: Days without dialysis within 28 days from enrollment
Measure: Dialysis-free days Time: 28 days from enrollmentDescription: Days without vasopressors within 28 days from enrollment
Measure: Vasopressor-free days Time: 28 days from enrollmentDescription: Days without need for ICU admission within 28 days from enrollment
Measure: ICU-free days Time: 28 days from enrollmentDescription: Total number of patient deaths within 28 days from enrollment
Measure: 28-day mortality Time: 28 days from enrollmentDescription: Anti-SARS-CoV-2 IgG antibody titers
Measure: Anti-SARS-CoV-2 antibody titers Time: days 0, 1, 7 and 14 of enrollmentDescription: Levels of SARS-CoV-2 RNA in nasopharyngeal swabs (or other specimen types as available) using RT-PCR
Measure: SARS-CoV-2 RNA by RT-PCR Time: days 0, 1, 7 and 14 of enrollmentAlphabetical listing of all HPO terms. Navigate: Correlations Clinical Trials
Data processed on September 26, 2020.
An HTML report was created for each of the unique drugs, MeSH, and HPO terms associated with COVID-19 clinical trials. Each report contains a list of either the drug, the MeSH terms, or the HPO terms. All of the terms in a category are displayed on the left-hand side of the report to enable easy navigation, and the reports contain a list of correlated drugs, MeSH, and HPO terms. Further, all reports contain the details of the clinical trials in which the term is referenced. Every clinical trial report shows the mapped HPO and MeSH terms, which are also hyperlinked. Related HPO terms, with their associated genes, protein mutations, and SNPs are also referenced in the report.
Drug Reports MeSH Reports HPO Reports